MLYSNasdaqPharmaceutical PreparationsFiscal year ends December 31

Mineralys Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$20.92+0.62 (+3.05%)

Close on Oct 19, 2026

Market cap: $1.77B
P/E (TTM): –
Dividend yield: –

Mineralys Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Research & Development	132	169	70	26
General & Administrative	39	24	14	5.23
Operating Expenses	171	192	85	31
Operating Income	-171	-192	-85	-31
Other Non-Operating Income	16	15	13	1.68
Income Tax Expense	0	–	–	–
Net Income	-155	-178	-72	-30
EPS (Basic)(per share)	-2.29	-3.66	-1.99	-5.77
EPS (Diluted)(per share)	-2.29	-3.66	-1.99	-5.77
Shares Outstanding (Basic, Weighted)(shares)	68	49	36	5.17
Shares Outstanding (Diluted, Weighted)(shares)	68	49	36	5.17
EBITDA	-171	-192	-85	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -36.9%

Financial strength

Current ratio: 34.46
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 715.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 3.22
Dividend yield: –